| |
| |
|
| Insider
Information: |
Stahl Neil |
| Relationship: |
EVP Research and Devel... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
50,999 |
|
|
Indirect Shares
|
10,439 |
|
|
| Direct
Value |
$49,290,024 |
|
|
|
Indirect Value
|
$10,089,189 |
|
|
| Total
Shares |
61,438 |
|
|
| Total
Value |
$59,379,213 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 57.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Regeneron Pharmaceuticals Inc |
REGN |
EVP Research and Devel... |
2024-02-26 |
50,999 |
2024-02-26 |
10,439 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
140 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-02-27 |
4 |
AS |
$435.93 |
$4,680,460 |
D/D |
(10,349) |
11,380 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-04-14 |
4 |
AS |
$517.99 |
$2,864,307 |
D/D |
(5,497) |
11,380 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
officerTitle |
• – – |
2006-02-03 |
4 |
D |
$16.40 |
$252,576 |
D/D |
(15,401) |
11,726 |
|
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Therap & Clin Prog Dev |
• – – |
2006-10-31 |
4 |
D |
$20.12 |
$252,526 |
D/D |
(12,551) |
9,647 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Research & Devel Sciences |
• – – |
2007-04-20 |
4 |
D |
$26.09 |
$365,573 |
D/D |
(14,012) |
15,285 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Research & Devel Sciences |
• – – |
2008-09-29 |
4 |
D |
$23.28 |
$341,820 |
D/D |
(14,683) |
10,667 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2009-07-24 |
4 |
D |
$20.14 |
$1,260,301 |
D/D |
(62,577) |
27,236 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2011-04-04 |
4 |
D |
$45.53 |
$2,649,527 |
D/D |
(58,193) |
84,465 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2011-09-06 |
4 |
D |
$65.76 |
$3,226,054 |
D/D |
(49,058) |
84,110 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-02-13 |
4 |
D |
$113.35 |
$4,019,844 |
D/D |
(35,464) |
90,323 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-02-14 |
4 |
D |
$111.01 |
$3,210,187 |
D/D |
(28,918) |
111,405 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res & Dev Sciences |
• – – |
2012-06-18 |
4 |
D |
$115.29 |
$6,475,609 |
D/D |
(56,168) |
98,032 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-08-28 |
4 |
D |
$145.70 |
$3,368,001 |
D/D |
(23,116) |
76,005 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
• – – |
2012-11-20 |
4 |
D |
$167.17 |
$5,039,005 |
D/D |
(30,143) |
83,478 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
• – – |
2012-12-14 |
4 |
D |
$179.13 |
$1,502,184 |
D/D |
(8,386) |
43,036 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2013-05-10 |
4 |
D |
$268.40 |
$8,696,160 |
D/D |
(32,400) |
72,026 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2013-12-16 |
4 |
D |
$272.73 |
$2,536,934 |
D/D |
(9,302) |
19,686 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-02-12 |
4 |
D |
$324.44 |
$10,361,316 |
D/D |
(31,936) |
47,003 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-08-06 |
4 |
D |
$336.11 |
$6,894,624 |
D/D |
(20,513) |
28,014 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-11-18 |
4 |
D |
$406.93 |
$4,659,349 |
D/D |
(11,450) |
18,834 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2015-11-05 |
4 |
D |
$567.63 |
$32,865,209 |
D/D |
(57,899) |
64,130 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-01 |
4 |
D |
$464.98 |
$3,595,225 |
D/D |
(7,732) |
26,762 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-14 |
4 |
D |
$475.56 |
$5,577,368 |
D/D |
(11,728) |
32,517 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-21 |
4 |
D |
$510.02 |
$5,964,174 |
D/D |
(11,694) |
32,256 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2018-05-23 |
4 |
D |
$293.68 |
$4,501,821 |
D/D |
(15,329) |
43,380 |
0 |
- |
|
140 Records found
|
|
Page 2 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
